but not that of s.c.-apomorphine (dopamine receptor agonist), and this effect of U-50,488H was completely re versed by pretreatment with nor-binaltorphimine, i.c.v. These results suggest that coadministration of K agonists can suppress the dopamine-related hyperlocomotion of p-agonists without decreasing the anti nociception of fir-agonists in mice.
The i and 8-agonists are known to have similar effects in several pharmacological actions, whereas p and K agonists appear to have different and/or opposite effects. Spinal and supraspinal a-adrenergic systems play an im portant role in the antinociceptive effects of the p-agonist morphine (1) . In contrast, the 5-HTergic but not the NAergic system is involved in mediating the antinocicep tive action of U-50,488H, a selective K-agonist (2) . Whereas fir and 5-opioid receptors are coupled to K+ channels, K-receptors are linked to voltage-dependent Cat+-channels in the mouse dorsal root ganglion neurons (3) . It has been reported that p-agonists produce an anti diuretic action, whereas K-agonists increase diuresis (4) . Treatments with p and K-agonists produce hyperthermia and hypothermia, respectively (5) . Administration of a KK agonist elicits a sedative action in contrast to the stimulant effect of ,u and o-agonists on locomotor activity in mice (6, 7) . Drug discrimination studies suggest that the discriminative properties of K-agonists are quite differ ent from those of ,u-agonists (8) (9) (10) . The p-agonists, but not K-agonists, are self-administered and facilitate brain self-stimulation (11) (12) (13) . In the place-conditioning para digm, mice and rats prefer an environment associated with administration of p and 5-agonists but, avoid an environ ment associated with the administration of K-agonists (14) (15) (16) , suggesting that either p or 3-agonists exert a euphoric effect, while s-agonists appear to be disphoric.
Activation of DAergic systems after administration of morphine and other p-opioids can elicit not only a motor activating effect but also a reinforcing effect (17) . Further more, Koob (18) proposed that the mesolimbic DAergic projection is a key component of the opioid reward mechanism. These findings indicate that although both p and K-agonists produce the antinociceptive effects through different mechanisms, there may be opposing properties of , e and s-agonists on some pharmacological actions, especially the DA-related actions such as motor activating and reinforcing effects. Thus, we hypothesized that one of the most important investigations for opioids is to determine if there is a negative modulation by ic agonists on the morphine-induced facilitation of central DAergic systems. Regarding the hypothesis that there may be useful interactions among opioid receptors, we in vestigated the effects of s-agonists on the morphine-in duced supraspinal antinociception and locomotor enhanc ing action in mice.
MATERIALS AND METHODS

Animals
Male ddY mice (18 25 g) were obtained from Tokyo Animal Laboratories, Inc. (Tokyo). The mice were housed at a room temperature of 22± 1 C with a 12-hr light-dark cycle (lights on 8:00 AM to 8:00 PM). Food and water were available ad libitum.
Antinociceptive assay
The antinociceptive test used in this study was deter mined by using a 551C hot-plate as the nociceptive stimu lus with the latency to paw-tap, paw-lick or an attempt to escape by jumping taken as the endpoint. Prior to drug ad ministration, control latencies were determined. To pre vent tissue damage, the mice that showed no response within 60 sec (cut-off time) were removed from the hot plate. The percent of antinociception was calculated ac cording to the following formula:
° antinocicep tion = 100 x (test latency control latency)/(60 sec con trol latency). Morphine or U-50,488H was given into the lateral cerebral ventricle of unanesthetized mice. The unilateral injection site was approximately 2 mm from either side of the midline on a line drawn through the an terior roots of the ears (19) . The injection was made with a 2-mm double-needle (Natsume Seisakusho Co., Ltd., Tokyo) attached to a 25-pl Hamilton microsyringe. Solu tions were injected in a volume of 5 -10 p1 per mouse over a period of 10 sec. Antinociception was tested 10 min (peak time) after treatment with morphine or U-50,488H, i.c.v. Nlz (35 mg/kg, s.c.; p1-antagonist), 3-FNA (1 pg, i.c.v.; pl/p2-antagonist), BNTX (3 ng, i.c.v.; 51-an tagonist), NTB (12 ng, i.c.v.; o2-antagonist), NTI (5 ng; 61/52-antagonist) and nor-BNI (1 ug, i.c.v.; K-antagonist) were given to mice 24 hr, 24 hr, 20 min, 20 min, 20 min and 30 min prior to the morphine treatment, respectively, according to the previous reports (25 30) . In combina tion studies, U-50,488H was coadministered with mor phine. Mice were pretreated s.c. with DSP-4 (a selective denervation tool for NAergic nerves (20) ) in a dose of 80 mg/kg 72 hr prior to treatment with morphine or U 50,488H, i.c.v. The 5-HT synthesis inhibitor PCPA was given s.c. at a dose of 200 mg/kg/day for 3 days; the an tinociceptive assay was performed on the day 4.
Locomotor assay
The locomotor activity of mice was measured by an am bulometer (ANB-M20, O'hara Co., Ltd., Tokyo). The principle of the device and the measurement method have been described in detail by Hirabayashi and Alam (21) . Briefly, a mouse was placed in a tilting-type round activity cage (20 cm in diameter and 19 cm in height). Any slight tilt of the activity cage caused by horizontal movement of the animal was detected by microswitches. Total activity counts in each 10-min segment were automatically record ed for 30 min prior to the injections and for 180 min fol lowing morphine, U-50,488H or DPDPE administration. U-50,488H (i.c.v.) was coadministered with morphine or DPDPE, i.c.v. /3-FNA at a dose of 1.0 pg and nor-BNI at a dose of 1.0 pg were given i.c.v. to mice 24 hr and 30 min prior to morphine treatment, respectively. To produce the destruction of central DAergic neurons, mice were treated with a 25 pg dose of 6-OHDA, i.c.v. 72 hr prior to i.c.v. administered morphine. Additionally, desipramine (25 mg/kg, s.c.) was given to mice 10 min prior to the 6 OHDA (i.c.v.) to block the uptake of 6-OHDA into NA ergic terminals (22) . Furthermore, we investigated the influence of s.c.-administered x-agonists in the s.c. mor phine-induced locomotion. Saline (0.1 ml/10 g of body weight); U-50,488H; or E-2078, a systemically active dy norphin analog (23), was given s.c. 10 min prior to the treatment with 10 mg/kg morphine (s.c.).
To examine the influences of i.c.v.-U-50,488H on the hyperlocomotion of the DA receptor agonist apomor phine, mice were treated with apomorphine in a dose of 0.5 and 1.0 mg/kg (s.c. (St. Louis, MO, USA). Sulpiride (Dogmatyl®) was ob tained from Fujisawa Ind., Co. (Osaka). E-2078 was a gift from Eisai Co., Ltd. (Tsukuba). 6-OHDA was dis solved in 0.9010 NaCl containing 10 mM ascorbic acid. Other drugs were dissolved in 0.9% NaCI. All doses refer to the salt forms of the drugs.
Statistical analysis
The data were presented as the mean±S.E.M. One way repeated analysis of variance (ANOVA) followed by the Newman-Keuls multiple comparison test was used for statistical evaluations. ED50 values of an opioid to induce antinociception and its 95010 confidence limits were deter mined by the linear regression lines. To investigate the an tinociceptive interaction between i.c.v.-morphine and -U 50,488H, we used isobolographic analysis (24, 25) . The ED50 value of i.c.v.-morphine was plotted on the ordinate and the ED50 value of i.c.v.-U-50,488H, on the abscissa. A theoretical line of the additive interaction was drawn by connecting the ED50 value for i.c.v.-morphine and -U 50,488H. For each morphine-U-50,488H combination, the ED50 value along with the 95% confidence limit was calculated for each mixture. For each combination, there also exists a theoretical additive ED50 value that would be expected if the drug interaction was additive. Pretreatment with nor BNI, but not i3-FNA and NTI, completely abolished the antinociceptive activity of 50 yg U-50,488H (Fig. 2) .
As shown in Table 1 , ED50 values of i.c.v.-morphine-in duced antinociception in either DSP-4 or PCPA-treated mice were significantly increased in comparison with those in the control non-pretreated animals. The inhibi tory potency of DSP-4 on the antinociception of mor phine was greater than that of PCPA.
The antinociceptive effect produced by i.c.v.-U 50,488H was significantly blocked by PCPA, while DSP-4 had no effect on the antinociception of i.c.v.-U-50,488H (Fig. 2) .
The ED50 value (with its 95% confidence limits) of i.c.v.-U-50,488H was 79.68 (63.24-108.18) ,Cg. The anti nociceptive activity of i.c.v.-morphine in combination with i.c.v.-U-50,488H statistically showed the additive effect (Fig. 3) . (Fig. 6) . On the other hand, the locomotor activity induced by s.c.-apomorphine was dose-dependently increased. The mean total counts after treatments with 0.5 and 1.0 mg/kg apomorphine in combination with i.c.v.-saline were 194.7-L27.1 and 329.5 ±28.7 counts/3 hr, respec tively. Both SCH23390 and sulpiride exerted a significant inhibiting effect on the locomotor enhancing action in duced by 1.0 mg/kg apomorphine in combination with i.c.v.-saline (P<0.01, Fig. 7) . However, i.c.v.-U 50,488H failed to inhibit the s.c.-apomorphine-induced locomotor enhancing action (Fig. 7) . As shown in Fig. 8 , U-50,488H at i.c.v.-doses that alone exerted little or no antinociceptive effects markedly suppressed the i.c.v.-morphine-induced locomotor en hancing action and Straub tail without decreasing the an tinociception of morphine. The locomotor ratios in the presence of 3 and 10 pg U-50,488H were 0.540 and 0.372, respectively. The potency ratios for Straub tail in combi nation with 3 and 10 pg U-50,488H were 0.175 and 0.044, respectively. (27, 28) . It is essential to have highly selective opioid antagonists as pharmacological tools to investigate the pharmacological effects that are mediated by different types of opioid receptors.
Pasternak's group has proposed that ~-FNA is a mixed p1/p2-antagonist, whereas Nlz selectively acts at the lit-receptors (29) . Fur thermore, a series of highly selective, non-peptide 5-recep tor antagonists, such as NTI, BNTX and NTB, have been recently synthesized (30 32) . Based on the antinocicep tive studies, it is proposed that BNTX and NTB selective ly act at the 51 and 62 receptors, respectively, while NTI is a non-selective 5-antagonist (31-33). Moreover, Takemori et al. (34) have reported that nor-BNI is a high ly selective K-antagonist. Under the present conditions, the treatment with each antagonist hardly affected the naive mice and shows a high selectivity for each opioid receptor (29) (30) (31) (32) (33) (34) .
Our present findings suggest that i.c.v.-morphine-in duced supraspinal antinociception against the nociceptive stimulus of a 55V hot-plate may be mediated through Pi and p2-receptors, but not 5 and K-receptors. In contrast, the expression of the i.c.v.-U-50,488H-induced anti nociception was due to central K-receptors, but not p and 5-receptors.
Systemic injection of DSP-4 is known to cause a selec tive degeneration of the central NAergic pathway. In deed, Nakazawa et al. (20) have reported that s.c.-DSP-4 completely reduced the levels of NA in the mouse spinal cord without modifying the levels of DA and 5-HT. Addi tionally, we also observed the NA depletion of the mouse whole brain by DSP-4 (M. Narita et al., unpublished data). In the present study, we found that the antinocicep tive activity induced by i.c.v.-morphine was drastically in hibited by pretreatment with s.c.-DSP-4, whereas DSP-4 had no effect on the i.c.v.-U-50,488H-induced anti nociception. On the contrary, PCPA, a 5-HT synthesis inhibitor (20) , was capable of suppressing either i.c.v. morphine or -U-50,488H-induced antinociception. Our results further suggest both NAergic and 5-HTergic invol vements in the mediation of the antinociceptive action of morphine administered i.c.v. In contrast, the i.c.v.-U 50,488H-induced antinociceptive effect appears to depend on 5-HTergic but not NAergic mechanisms. Although both NAergic and 5-HTergic systems have been reported to be involved in the antinociceptive action of p-agonists such as morphine (35, 36) , NAergic mechanisms may be more important in the mediation of antinociception by morphine (37) . In the present study, the inhibitory po tency of PCPA on the antinociception of morphine was weaker than that of DSP-4, indicating that in the media tion of morphine-induced antinociception, the NA sys tems are more important than the 5-HTergic systems. On the other hand, Ho and Takemori (2, 38, 39) have shown that the antinociceptive action of U-50,488H is probably mediated by the release of 5-HT in the brain and spinal cord. However, they have suggested that the antinocicep tive action of U-50,488H is not mediated by the NAergic system because NA receptor antagonists failed to reverse the effect of U-50,488H. These reports support our data. As shown in the combination studies, the antinocicep tive interaction between i.c.v.-morphine and -U-50,488H was an additive effect. It is presently unclear what factors contribute to the additive effect. We expected these combi nations to produce a synergic or antagonistic effect be cause the antinociception of morphine and U-50,488H are mediated through different mechanisms. This additive effect appears to result from the intricate interactions be tween NAergic and 5-HTergic systems in the mouse brain.
The opioid analgesics, of which the prototype is mor phine, are of importance in the control of moderate to severe pain. Unfortunately, most of them possess high dependence liability (40) . An enduring aim in opioid research has been to develop strong analgesics devoid of morphine-like side effects. In the previous study, we found that inactivation of the K-opioid system may poten tiate the development of tolerance to morphine anti nociception in mice and may aggravate the naloxone precipitated body weight loss in morphine-dependent mice and rats (41) . From the above findings, we therefore hypothesized that there may be an inhibitory K-opioid mechanism serving as negative modulation against the ac tivation of p-receptors. Furthermore, these observations support the probability that coadministration of ic agonists may be a good means for producing a potent an tinociceptive effect with decreasing some side-effects of morphine.
The present results clearly demonstrated that the activa tion of central p-receptors by i.c.v.-morphine produced the potent locomotor enhancing action, and this effect was mainly mediated through activation of presynaptic DA-containing neurons. On the other hand, it has been proposed by our previous report that the expression of i.c.v.-morphine-induced Straub tail may also be due to the activation of central DAergic systems (26) . More im portantly, we presently found through the interactions be tween p and ic-agonists that administration of U-50,488H could attenuate the morphine-induced locomotor enhanc ing action as well as Straub tail, but not supraspinal an tinociception. These findings further suggest that tonic activation of K-receptors inhibits the morphine-induced DA-related behaviors without blocking the antinocicep tive activity of morphine.
DPDPE, a selective o-agonist, administered i.c.v. pro duced a dose-dependent locomotion, and this hyperloco motion of i.c.v.-DPDPE was markedly antagonized by i.c.v.-pretreatment with NTI. Interestingly, i.c.v.-U 50,488H significantly abolished the i.c.v.-DPDPE-in duced locomotor enhancing action. Additionally, our previous reports indicate that 5-receptors play a partial role in the morphine-induced hyperlocomotion and excita tion of DA systems, but not antinociception (42, 43) . From these findings, 6-receptors as well as p-receptors play an important role as modulators of the expression of opioid-induced hyperlocomotion related to DA transmis sion, and the increased activity of K-opioid systems can lead to suppression of the hyperlocomotion of p15 agonists.
An interesting neurochemical interaction between mor phine and U-50,488H was also found. We observed at 90 min after the i.c.v.-treatment that 10 pg morphine elevat ed the levels of DOPAC and HVA in the mouse whole brain, and these elevations were drastically abolished by coadministration of 10 pg U-50,488H without changing DA steady-state levels (44) . Furthermore, activation of central p/3-opioid receptors by treatment with systemic morphine increased the DA-turnover in the mouse limbic forebrain (42, 45) , in which the main field of the meso limbic DA terminal field exists, and the enhancement of the DA-turnover by morphine was dose-dependently abolished by pretreatment with systemic U-50,488H (45) . These findings suggest that an increased activity of K opioid systems may result in a suppression of the p/o agonist-induced DA release.
A low dose of apomorphine stimulates presynaptic DA autoreceptors and inhibits the release of DA (46) . However, a high dose of apomorphine administered sys temically stimulates the postsynaptic D2-receptors (47) . Furthermore, it has been recently reported that the loco motor enhancing action induced by s.c.-apomorphine in a dose of 1 mg/kg was suppressed by pretreatment with the selective D,-antagonist SCH23390 in male ddY mice (48) . In the present study, we found either SCH23390 or sulpiride (D2-antagonist) was capable of suppressing the locomotor enhancing action induced by s.c. It is well known that the release of DA in the nucleus ac cumbens after p-agonist administration can elicit not only a motor-activating effect, but also a positive reinforcing effect in the rodent (17) . Therefore, the possible blockade of the reinforcing effects elicited by opioids and psychostimulants may result from, at least in part, an in creased activity of K-opioid systems. Indeed, we have the data that tonic activation of K-receptors blocks the rein forcing effects of cocaine (49) and morphine (unpublished data).
In conclusion, the selective K-agonist U-50,488H at i.c.v.-doses that alone exerted little or no antinociceptive effects can strongly attenuate the i.c.v.-morphine-induced DA-related behaviors, such as locomotor enhancing ac tion and Straub tail, without decreasing the antinocicep tive activity. In view of the present work, including our previous studies, it is tempting to speculate that the ade quate coactivation of p and K-receptors may produce a potent antinociceptive activity along with a decrease in some side-effects of opioids.
